Last €0.12 EUR
Change Today -0.002 / -1.64%
Volume 0.0
BXA On Other Exchanges
Symbol
Exchange
Athens
Berlin
As of 1:20 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

lavipharm s.a. (BXA) Snapshot

Open
€0.12
Previous Close
€0.12
Day High
€0.14
Day Low
€0.12
52 Week High
11/7/13 - €0.17
52 Week Low
06/18/14 - €0.10
Market Cap
6.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
51.1M
EX-Date
06/5/09
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LAVIPHARM S.A. (BXA)

Related News

No related news articles were found.

lavipharm s.a. (BXA) Related Businessweek News

No Related Businessweek News Found

lavipharm s.a. (BXA) Details

Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company primarily offers a range of pharmaceutical products in the areas of cardiology, chronic pain and oncology, central nervous system, general medicine and respiratory system, gastrointestinal system, and urology. It also provides over the counter antiseptics, analgesics, gynecology, anti-lice treatment, and natural products; and dermocosmetics, such as skincare products. In addition, the company offers Trinipatch, a nitroglycerine transdermal delivery system used for the prevention of angina. Its product pipeline includes nicotine transdermal system for smoking cessation; various OTC products for the symptoms of common cold, oral hygiene, and excessive excretion of shawl; and food supplements. The company primarily serves health professionals, physicians, and pharmacists. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece.

Founded in 1911

lavipharm s.a. (BXA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lavipharm s.a. (BXA) Key Developments

Lavipharm S.A. Announces Earnings Results for the Year Ended December 31, 2011

Lavipharm S.A. announced earnings results for the year ended December 31, 2011. For the year, the company reported total revenue of EUR 168.7 million against EUR 168.43 million a year ago. Operating loss was EUR 3.99 million against operating income of EUR 6.14 million a year ago. Pre-tax loss was EUR 13.44 million against pre-tax income of EUR 0.88 million a year ago. Total net loss was EUR 10.39 million against EUR 3.75 million a year ago. Cash from operating activities was EUR 14.88 million against EUR 1.13 million a year ago. Capital expenditures was EUR 0.82 million against EUR 0.47 million a year ago. Negative return on equity was 59.44% against 13% a year ago. Negative return on assets was 7.13% against 1.95% a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BXA:GR €0.12 EUR -0.002

BXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BXA.
View Industry Companies
 

Industry Analysis

BXA

Industry Average

Valuation BXA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LAVIPHARM S.A., please visit www.lavipharm.gr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.